Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial

Julius Simoni Leere; Jesper Karmisholt; Maciej Robaczyk; Simon Lykkeboe; Aase Handberg; Emilie Steinkohl; Jens Brøndum Frøkjær; Peter Vestergaard

doi:10.1016/S2213-8587(20)30063-2

Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial

Julius Simoni Leere^*, Jesper Karmisholt, Maciej Robaczyk, Simon Lykkeboe, Aase Handberg, Emilie Steinkohl, Jens Brøndum Frøkjær, Peter Vestergaard

^*Corresponding author

Research output: Contribution to journal › Journal article › Research › peer-review

6 Citations (Scopus)

Original language	English
Journal	The Lancet Diabetes and Endocrinology
Volume	8
Issue number	5
Pages (from-to)	407-417
Number of pages	11
ISSN	2213-8587
DOIs	https://doi.org/10.1016/S2213-8587(20)30063-2
Publication status	Published - May 2020

Access to Document

10.1016/S2213-8587(20)30063-2

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Cite this

Leere, Julius Simoni ; Karmisholt, Jesper ; Robaczyk, Maciej ; Lykkeboe, Simon ; Handberg, Aase ; Steinkohl, Emilie ; Brøndum Frøkjær, Jens ; Vestergaard, Peter. / Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA) : a randomised, double-blind, placebo-controlled, phase 3 trial. In: The Lancet Diabetes and Endocrinology. 2020 ; Vol. 8, No. 5. pp. 407-417.

@article{6d77579d853f4de6b657e79ac412b11e,

title = "Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial",

author = "Leere, {Julius Simoni} and Jesper Karmisholt and Maciej Robaczyk and Simon Lykkeboe and Aase Handberg and Emilie Steinkohl and {Br{\o}ndum Fr{\o}kj{\ae}r}, Jens and Peter Vestergaard",

year = "2020",

month = may,

doi = "10.1016/S2213-8587(20)30063-2",

language = "English",

volume = "8",

pages = "407--417",

journal = "The Lancet Diabetes & Endocrinology",

issn = "2213-8587",

publisher = "The Lancet Publishing Group",

number = "5",

}

Leere, JS , Karmisholt, J , Robaczyk, M , Lykkeboe, S , Handberg, A, Steinkohl, E, Brøndum Frøkjær, J & Vestergaard, P 2020, 'Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Diabetes and Endocrinology, vol. 8, no. 5, pp. 407-417. https://doi.org/10.1016/S2213-8587(20)30063-2

Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA) : a randomised, double-blind, placebo-controlled, phase 3 trial. / Leere, Julius Simoni ; Karmisholt, Jesper ; Robaczyk, Maciej ; Lykkeboe, Simon ; Handberg, Aase; Steinkohl, Emilie; Brøndum Frøkjær, Jens ; Vestergaard, Peter.

In: The Lancet Diabetes and Endocrinology, Vol. 8, No. 5, 05.2020, p. 407-417.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA)

T2 - a randomised, double-blind, placebo-controlled, phase 3 trial

AU - Leere, Julius Simoni

AU - Karmisholt, Jesper

AU - Robaczyk, Maciej

AU - Lykkeboe, Simon

AU - Handberg, Aase

AU - Steinkohl, Emilie

AU - Brøndum Frøkjær, Jens

AU - Vestergaard, Peter

PY - 2020/5

Y1 - 2020/5

UR - http://www.scopus.com/inward/record.url?scp=85083439455&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(20)30063-2

DO - 10.1016/S2213-8587(20)30063-2

M3 - Journal article

C2 - 32333877

AN - SCOPUS:85083439455

VL - 8

SP - 407

EP - 417

JO - The Lancet Diabetes & Endocrinology

JF - The Lancet Diabetes & Endocrinology

SN - 2213-8587

IS - 5

ER -